Compare Sana Biotechnology Inc (SANA) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs TotalEnergies SE — how do they compare? Sana Biotechnology Inc trades at $3.19 (market cap $947.48M), while TotalEnergies SE trades at $91.43 (market cap $200.95B). The key difference: TotalEnergies SE is far larger — about 212.1× Sana Biotechnology Inc's market cap, and TotalEnergies SE pays a 4.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TTE | |
|---|---|---|
Market Cap | $947.48M | $200.95B |
Sector | Health | Energy |
52-Week High | $5.92 | $93.60 |
52-Week Low | $2.68 | $57.39 |
Enterprise Value | $860.73M | $231.94B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $244.17 million for 2025, with ROE at -152.87%. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data for type 1 diabetes treatment.
Analyst consensus is strongly bullish with 81.82% buy ratings, but high cash burn and negative earnings pose significant risks. Upside potential hinges on clinical success and future profitability, while downside risks include sustained losses and competitive pressures in biotechnology.
TotalEnergies (TTE) trades at $90.10, up 1.7% with bullish technical momentum. The stock shows strong fundamentals with a P/E of 11.28, ROE of 14.56%, and consistent earnings beats in recent quarters. Recent developments include $10 billion Angola investment plans and progress on Papua LNG project. Cash flow improved to positive $358M in 2025 after three years of negative net cash flow, while revenue declined from $263.3B in 2022 to $182.3B in 2025.
TTE presents value opportunity with attractive valuation metrics and 57.6% analyst buy rating. Upside to $98 consensus target offers 8.8% potential return, supported by dividend yield and operational improvements. Key risks include energy price volatility and execution challenges in major projects. The company's strategic investments and efficiency initiatives position it for recovery despite recent revenue declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
